<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03119688</url>
  </required_header>
  <id_info>
    <org_study_id>207619</org_study_id>
    <nct_id>NCT03119688</nct_id>
  </id_info>
  <brief_title>To Assess the Mildness of a Cosmetic Cleanser in Healthy Participants Using the Forearm-Controlled Application Technique (FCAT)</brief_title>
  <official_title>A Clinical Study to Assess the Mildness of a Cosmetic Cleanser in Healthy Subjects Using the Forearm-Controlled Application Technique (FCAT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical study is to assess the relative mildness of a cosmetic facial
      cleanser in comparison to water through repeated application to the volar forearm using the
      FCAT wash procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a test site randomized, examiner blinded, positive and negative-controlled,
      single-center; Forearm Controlled Application Technique clinical study in healthy
      participants to assess the mildness potential of a cosmetic facial cleansing product.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 8, 2017</start_date>
  <completion_date type="Actual">May 26, 2017</completion_date>
  <primary_completion_date type="Actual">May 26, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in visual assessment of dryness</measure>
    <time_frame>At Baseline and Day 5 (3 hours post last wash procedure)</time_frame>
    <description>Skin dryness will be assessed by a trained examiner according to following the scoring scale: 0 (No dryness); 1 (Patches of slight powederiness and occasional patches of small scales may be seen, distribution generalized.); 2 (Generalised slight powederiness, early cracking or occasional small lifting scales may be present); 3 (Generalised moderate powederiness and/or heavy cracking and lifting scales; 4 (Generalised heavy powederiness and/or heavy cracking and lifting scales); 5 (Generalised high cracking and lifting scales, eczematous change may be present, powederiness may be present but not prominent, may see bleeding crack); 6 (Generalised severe cracking, eczematous change may be present, bleeding cracks may be present, scale large may be beginning to disappear).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in visual assessment of redness</measure>
    <time_frame>At Baseline and Day 5 (3 hours post llast wash procedure)</time_frame>
    <description>Skin redness will be assessed by a trained examiner according to following the scoring scale: 0 (No redness); 1(Barely detectable redness); 2(Slight redness); 3 (Moderate redness); 4 (Heavy or substantial redness); 5 (Extreme redness); 6 (Severe Redness).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in visual assessment of dryness</measure>
    <time_frame>At Day 2, 3, 4 and 5 (3 hours post last wash procedure)</time_frame>
    <description>Skin dryness will be assessed by a trained examiner according to following the scoring scale: 0 (No dryness); 1 (Patches of slight powederiness and occasional patches of small scales may be seen, distribution generalized.); 2 (Generalised slight powederiness, early cracking or occasional small lifting scales may be present); 3 (Generalised moderate powederiness and/or heavy cracking and lifting scales; 4 (Generalised heavy powederiness and/or heavy cracking and lifting scales); 5 (Generalised high cracking and lifting scales, eczematous change may be present, powederiness may be present but not prominent, may see bleeding crack); 6 (Generalised severe cracking, eczematous change may be present, bleeding cracks may be present, scale large may be beginning to disappear).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in visual assessment of redness</measure>
    <time_frame>At Day 2, 3, 4 and 5 (3 hours post last wash procedure)</time_frame>
    <description>Skin redness will be assessed by a trained examiner according to following the scoring scale: 0 (No redness); 1(Barely detectable redness); 2(Slight redness); 3 (Moderate redness); 4 (Heavy or substantial redness); 5 (Extreme redness); 6 (Severe Redness).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline Transepidermal water loss (TEWL)</measure>
    <time_frame>At Baseline and Day 5 (3 hours post last wash procedure)</time_frame>
    <description>TEWL will be measured using Tewameter. An increase in TEWL values will show damage to the skin barrier function. TEWL values will be expressed in gram/square metre/hour (g/m^2/hr).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in skin moisturisation</measure>
    <time_frame>At Baseline and Day 5 (3 hours post last wash procedure)</time_frame>
    <description>Measurement of stratum corneum moisturisation will be performed by the electrical capacitance method with the Corneometer. Corneometer values lower than 30 instrumental units (i.u.) represents very dry skin, while values between 30 und 50 i.u are typically for dry skin on the forearm. An increase in Corneometer values corresponds to a skin-moisturising effect.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Skin Care</condition>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0.09 milliliters (ml) of the cleanser (test product) will be applied on the allocated site on forearm topically.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Positive Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Soap bar (positive control) will be applied on the allocated site on forearm topically.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference Product</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>0.09 ml of sterile water (Reference Product) will be applied on the allocated site on forearm topically.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test Product</intervention_name>
    <description>Micellar cleanser (0.09 ml)</description>
    <arm_group_label>Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Positive Control</intervention_name>
    <description>Bar Soap (rubbed for 6 seconds to generate a lather)</description>
    <arm_group_label>Positive Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Reference Product</intervention_name>
    <description>Sterile Water (0.09 ml)</description>
    <arm_group_label>Reference Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Demonstrates understanding of the study procedures, restrictions and willingness to
             participate as evidenced by voluntary written informed consent and has received a
             signed and dated copy of the informed consent form.

          -  Aged between 18 and 65 years inclusive.

          -  Good general and mental health with, in the opinion of the investigator or medically
             qualified designee no clinically significant and relevant abnormalities in medical
             history or upon physical examination.

          -  Intact skin at the proposed application site; volar forearm.

          -  Clinical assessment for eligibility by a dermatologist to ensure participant is free
             of clinically relevant dermatological conditions.

          -  Fitzpatrick phototype I to IV.

          -  Trained examiner scores of zero for dryness and redness for each volar forearm at
             Screening visit (Visit 1) and each allocated test site on each forearm at Baseline
             visit.

          -  Agreement to comply with the procedures and requirements of the study and to attend
             the scheduled assessment visits.

        Exclusion Criteria:

          -  Women who are known to be pregnant or who are intending to become pregnant over the
             duration of the study.

          -  Women who are breast-feeding

          -  Any history of significant dermatological diseases or conditions or medical conditions
             known to alter skin appearance or physiologic response (e.g. diabetes,) which could,
             in the opinion of the Investigator, preclude topical application of the
             investigational products and/or interfere with the evaluation of the test site
             reaction.

          -  Presence of open sores, pimples, or cysts at the application site.

          -  Active dermatosis (local or disseminated) that might interfere with the results of the
             study.

          -  Considered immune compromised.

          -  History of diseases aggravated or triggered by ultraviolet radiation.

          -  History of atopic dermatitis.

          -  Participants with dermatographism.

          -  Currently using any medication which in the opinion of the investigator, may affect
             the evaluation of the study product, or place the participant at undue risk.

          -  Use of the following topical or systemic medications: immunosuppressants,
             antihistamines, non-hormonal anti-inflammatory drugs, and corticosteroids upto 2 weeks
             before screening visit.

          -  Oral or topical treatment with vitamin A acid and/or its derivatives up to 1 month
             before the screening visit.

          -  Intention of being vaccinated during the study period or has been vaccinated within 3
             weeks of the screening visit.

          -  Currently receiving allergy injections, or received an allergy injection within 7 days
             prior to Visit 1, or expects to begin injections during study participation.

          -  Previous history of atopy, allergic reactions, irritation or intense discomfort
             feelings to topical-use products, cosmetics or medication.

          -  Known or suspected intolerance or hypersensitivity to the study materials (or closely
             related compounds) or any of their stated ingredients.

          -  Participation in another clinical study (including cosmetic studies) or receipt of an
             investigational drug within 30 days of the screening visit.

          -  Previous participation in this study.

          -  Recent history (within the last 5 years) of alcohol or other substance abuse.

          -  Intense sunlight exposure or sun tanning sessions, including use of self-tanning
             products on the test areas up to 14 days before the Screening evaluation.

          -  Intention of bathing (in the sea or pool), sauna, water sports, or activities that
             lead to intense sweating.

          -  Any Participant who, in the judgment of the Investigator and Dermatologist, should not
             participate in the study.

          -  Any skin marks on the test site that might interfere with the evaluation of possible
             skin reactions (e.g. pigmentation disorders, vascular malformations, scars, tattoos,
             excessive hair, numerous freckles).

          -  Prisoner or involuntary incarcerated participant

          -  Participant from an indigenous tribe.

          -  An employee of the sponsor or the study site or members of their immediate family.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Campinas</city>
        <state>SÃ£o Paulo</state>
        <zip>13084-791</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2017</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <pending_results>
    <submitted>April 20, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

